First, by investigating the prognostic impact of CXCR4 expression separately for CHOP and R-CHOP cohorts of a clinical DLBCL dataset and, second, by studying the association between CXCR4 surface expression and rituximab sensitivity in a panel of up to fourteen human DLBCL cell lines. This evidence concerns the gene CXCR4 and diffuse large B-cell lymphoma.